Performance in Delivery Q3 18-19

Id	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial	Comments
34565	16/EM/0376	211430	Leadership 301 / RENA 5488	Number Agreed	4	4	Date Agreed	31/12/2017	4	13/02/2018	4	Recruitment Finished	
34566	14/NW/1258	161891	ARAMIS - A Multinational, Randomised, DoubleBlind, PlaceboControlled, Phase III Efficacy And Safety Study Of ODM201 In Men With HighRisk NonMetastatic Castration Resistant Prostate Cancer	Number Agreed	3	3	Date Agreed	31/05/2020	5	09/02/2018	5	Recruitment Finished	
34567	14/EM/1307	165983	ESTHER - A DISEASE REGISTRY STUDY TO PROSPECTIVELY OBSERVE TREATMENT PATTERNS AND OUTCOMES IN PATIENTS WITH HER2-POSITIVE UNRESECTABLE LOCALLY ADVANCED OR METASTATIC BREAST CANCER ML29659	Number Agreed	12	12	Date Agreed	25/04/2018	22	16/03/2018	22	Recruitment Finished	
34568	16/LO/1625	173719	ARIADNE - Assessment of real life care-describing European heart failure management CARD 5390	Number Agreed	20	20	Date Agreed	29/04/2018	17	16/03/2018	17	Recruitment Finished	
34569	15/EM/0500	188865	QAW039 Respiratory Study - A 52-week, multicenter, randomized, double-blind, placebocontrolled study to assess the efficacy and safety of QAW039 when added to existing asthma therapy in patients with uncontrolled severe asthma	Number Agreed	5	5	Date Agreed	26/07/2018	1	28/08/2018	1	Recruitment Finished	
34570	16/NW/0305	201856	A Phase III, multicentre, randomised, double blind, parallel group, placebo controlled study to assess the efficacy and safety of one or more intradetrusor treatments of 600 or 800 units of DYSPORT® for the treatment of urinary incontinence in subjec	Number Agreed	4	4	Date Agreed	30/09/2019	3	01/10/2018	3	Recruitment Finished	

Id	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial	Comments
34571	15/NE/0278	183395	AZURE eyes - An open-label, randomized, active-controlled, parallel group, Phase-3b study of the efficacy, safety, and tolerability of 2mg aflibercept administered by intravitreal injections using two different treatment regimens to subjects with neo	Number Agreed	4	4	Date Agreed	30/04/2019	3	23/10/2018	3	Withdrawn By Sponsor	
34574	15/NW/0130	196702	'LUME BioNIS' A non-interventional biomarker study in patients with Non-Small Cell Lung Cancer (NSCLC) of adenocarcinoma tumour histology eligible for treatment with Vargatef® according to the approved label. CANC 4658	Number Agreed	2	2	Date Agreed	01/02/2019	0	01/11/2018	0	Withdrawn By Sponsor	